Document ID: chunk:federal_register_of_legislation:F2024L00045:reg:9:p3
Version: federal_register_of_legislation:F2024L00045
Segment Type: reg
Provision Reference: reg 9 (pt 3/6)
Character Range: 20720–23936

episode or persistent depressive disorder;
(20)      being in the menopausal transition or within the 2 years after the final menstrual period at the time of the clinical onset of major depressive disorder, major depressive episode or persistent depressive disorder;
Note: menopausal transition is defined in the Schedule 1 - Dictionary.
(21)      having another medical condition, including an endocrine, cardiovascular, respiratory, metabolic, infectious or neurological disorder, where the signs or symptoms of depression are directly related to the pathological process of the medical condition and not solely due to its psychosocial stress effects, at the time of the clinical onset of "depressive disorder due to another medical condition";
(22)      taking mefloquine or corticosteroids, excluding topical or inhaled corticosteroids, within the 30 days before the clinical onset of substance/medication-induced depressive disorder, where substance/medication-induced depressive disorder persists after the discontinuation or tapering of mefloquine or corticosteroid therapy;
(23)      using a psychoactive substance from the specified list of psychoactive substances at an intoxicant dose within the 30 days before the clinical onset of substance/medication-induced depressive disorder;
Note: intoxicant dose and specified list of psychoactive substances are defined in the Schedule 1 – Dictionary.
(24)      taking a drug that cannot be ceased or substituted in the long term and which is associated in the individual with the development of depressive symptoms during drug therapy and either:
(a)          the improvement of depressive symptoms within days or weeks of discontinuing or tapering drug therapy; or
(b)          the redevelopment of depressive symptoms on rechallenge with the same drug;
where the drug was being taken within the 30 days before the clinical onset of substance/medication-induced depressive disorder;
(25)      using a psychoactive chemical or substance at an intoxicant dose, which is associated in the individual with the development of depressive symptoms, and where the psychoactive chemical or substance was being taken within the 30 days before the clinical onset of substance/medication-induced depressive disorder;
Note: intoxicant dose is defined in the Schedule 1 – Dictionary.
(26)      having ceased or reduced therapeutic or illicit drug use or other substance use within the 30 days before the clinical onset of substance/medication-induced depressive disorder;
(27)      having an alcohol use disorder or a substance use disorder at the time of the clinical onset of substance/medication-induced depressive disorder;
(28)      having smoked tobacco products:
(a)          on an average of at least 20 cigarettes per day or the equivalent thereof in other tobacco products; and
(b)          for at least the 2 years before the clinical onset of major depressive disorder, major depressive episode, persistent depressive disorder, premenstrual dysphoric disorder or substance/medication-induced depressive disorder; and
if smoking has ceased before the clinical onset then that onset occurred within 6 months of cessation;
Note: cigarettes per day or the equivalent